Emmessar Biotech Intrinsic Value
EMMESSA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹9.00 | ₹7.20 - ₹10.80 | -70.0% | EPS: ₹0.40, Sector P/E: 12x |
| Book Value Method | asset | ₹16.00 | ₹14.40 - ₹17.60 | -46.7% | Book Value/Share: ₹16.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹9.00 | ₹8.10 - ₹9.90 | -70.0% | Revenue/Share: ₹4.00, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹12.00 | ₹10.80 - ₹13.20 | -60.0% | EBITDA: ₹1.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹18.57 | ₹14.86 - ₹22.28 | -38.1% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹9.00 | ₹8.10 - ₹9.90 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹9.00 | ₹8.10 - ₹9.90 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹12.00 | ₹10.80 - ₹13.20 | -60.0% | EPS: ₹0.40, BVPS: ₹16.00 |
Want to compare with current market value? Check EMMESSA share price latest .
Valuation Comparison Chart
EMMESSA Intrinsic Value Analysis
What is the intrinsic value of EMMESSA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Emmessar Biotech (EMMESSA) is ₹12.00 (median value). With the current market price of ₹30.00, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹9.00 to ₹18.57, indicating ₹9.00 - ₹18.57.
Is EMMESSA undervalued or overvalued?
Based on our multi-method analysis, Emmessar Biotech (EMMESSA) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.12 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Operating Margin | -331.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.22x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Emmessar Biotech
Additional stock information and data for EMMESSA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹2 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |